Skip to main content
. 2023 Apr 12;109(5):1330–1341. doi: 10.1097/JS9.0000000000000370

Figure 1.

Figure 1

Study design and prognostic value of HER2 expression. (A) Study profile; (B–D) Kaplan–Meier estimates of overall survival according to HER2 expression in patients with stages II and III disease (B), patients with stage II disease (C), and patients with stage III disease (D). HER2, human epidermal growth factor receptor 2; HR, hazard ratio.